Abyss EyeAbyss Eye🃏All Fomantis cards
Ask about Fomantis
Fomantis #3 Pokémon card from Japanese Abyss Eye
Japanese

Fomantis 3/81

Abyss Eye· Language: Japanese

Find this card on eBay

Affiliate link · we may earn commission

Fomantis #3 from Japanese Abyss Eye currently trades at $1.44 raw, with PSA 10 copies reaching $36.96 — a 25.7x grade premium.
Current Prices (USD)
Ungraded
$1.44
PSA 7
$11.90
PSA 8
$11.90
PSA 9
$11.90
PSA 10
$36.96
ACE 10
BGS 10 Black
$240.00
CGC 10 Pristine
$40.00
Compare on eBay

Affiliate link · we may earn commission

Quick price facts

Fomantis 3/81 from Abyss Eye has a current raw market value of $1.44.

Current raw value
$1.44
PSA 9 value
$11.90
PSA 10 value
$36.96
PSA 10 premium vs raw
25.7× raw
View all cards from Abyss Eye
Collector Intel
25.7x
Raw → PSA 10
High-risk grade
8.3x
Raw → PSA 9
Grade multiplier

Calculated from price history, PSA population data, and market trends. Not financial advice.

Grading Calculator

Based on PSA Standard tier (~$25 USD). Assumes a perfect PSA 10 result — actual outcome depends on card condition.

⚠️ High-variance grade. PSA 10 is 26x the raw price. The expected value accounts for the realistic probability.
$1
Buy Raw
~$25
Grading Fee
PSA Standard
$37
PSA 10 Value
+$11
Best Case (PSA 10)
if you pull a 10
Grade Multiples vs Raw
PSA 9$128.3x raw
PSA 10$3725.7x raw

Frequently asked questions

How much is Fomantis #3 from Japanese Abyss Eye worth?+
Fomantis #3 from Japanese Abyss Eye is currently worth Raw: $1.44, PSA 9: $11.90, PSA 10: $36.96 based on recent sold listings. Prices update daily from real eBay sales.
Is Fomantis #3 worth grading?+
The PSA 10 price of $36.96 is 25.7× the raw price of $1.44. After a ~$25 grading fee, a PSA 10 result would net approximately $35.52 — assuming the card grades a 10.
Where do PokePrices Fomantis #3 prices come from?+
Prices are tracked nightly from real sold listings on PriceCharting (raw, PSA 9 and PSA 10). PSA population data is sourced from PSA's public reports. We do not use asking prices — only confirmed sales.